Home » Baxter Presents Data From Interim Analyses of Phase III Clinical Trial
Baxter Presents Data From Interim Analyses of Phase III Clinical Trial
Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency who received Baxter’s HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies in Istanbul, Turkey.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May